NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
NOVARTIS AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026
$150.20−0.42 (-0.28%)
Close on Oct 19, 2026
- Market cap
- $287.48B
- P/E (TTM)
- 21.0
- Dividend yield
- –
Novartis statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Novartis | Industry median |
|---|---|---|
| Market Cap | $286.60B | $166.30M |
| Enterprise Value | $279.39B | $88.19M |
| PE Ratio | 21.01 | 20.44 |
| PB Ratio | 6.90 | 2.03 |
| P/FCF Ratio | 16.29 | 17.44 |
| P/OCF Ratio | 14.97 | 12.98 |
Enterprise value
| Measure | Novartis | Industry median |
|---|---|---|
| EV / EBITDA | 15.84 | 14.65 |
| EV / EBIT | 15.84 | 19.00 |
| EV / FCF | 15.88 | 20.86 |
Income (trailing twelve months)
| Measure | Novartis | Industry median |
|---|---|---|
| Gross Profit | $42.98B | $105.94M |
| Operating Income | $17.64B | -$21.40M |
| Pretax Income | $16.35B | -$14.34M |
| Net Income | $13.98B | -$22.46M |
| EBITDA | $17.64B | -$16.91M |
| EPS (Diluted) | $7.15 | -$0.83 |
Returns
| Measure | Novartis | Industry median |
|---|---|---|
| Return on Equity (ROE) | 33.5% | -53.2% |
| Return on Assets (ROA) | 12.4% | -40.9% |
| Return on Invested Capital (ROIC) | 43.5% | -32.4% |
| Return on Capital Employed (ROCE) | 19.5% | -38.1% |
Growth
| Measure | Novartis | Industry median |
|---|---|---|
| Net Income Growth (YoY) | 17.1% | -35.2% |
| EPS Growth (YoY) | 21.8% | -26.2% |
| FCF Growth (YoY) | 8.26% | 2.34% |
| EPS Growth (3Y CAGR) | 31.1% | -0.17% |
| EPS Growth (5Y CAGR) | 15.2% | 3.77% |
Balance sheet
| Measure | Novartis | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.62B | $61.43M |
| Net Cash (Debt) | $7.62B | $15.35M |
| Net Cash Per Share | $3.99 | $0.66 |
| Equity (Book Value) | $41.54B | $49.09M |
| Book Value Per Share | $21.77 | $1.37 |
| Tangible Book Value | -$27.30B | $23.52M |
| Working Capital | -$4.40B | $76.81M |
Financial position
| Measure | Novartis | Industry median |
|---|---|---|
| Current Ratio | 0.86 | 3.34 |
| Quick Ratio | 0.54 | 2.44 |
| Interest Coverage | 15.42 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Novartis | Industry median |
|---|---|---|
| Operating Cash Flow | $19.14B | -$12.35M |
| Capital Expenditures | -$1.55B | -$1.08M |
| Free Cash Flow | $17.60B | -$20.22M |
| FCF Per Share | $9.22 | -$0.42 |
Efficiency
| Measure | Novartis | Industry median |
|---|---|---|
| Inventory Turnover | 2.19 | 2.70 |
| Profits Per Employee | $28.48M | -$703.34K |
| Employee Count | 491 | 74 |
Dividends and yields
| Measure | Novartis | Industry median |
|---|---|---|
| Earnings Yield | 4.88% | -23.3% |
| FCF Yield | 6.14% | -8.72% |
| Buyback Yield | 3.21% | -0.59% |
| Shareholder Yield | 3.21% | 0.00% |
| Payout Ratio | 55.9% | 46.5% |
| FCF Payout Ratio | 44.4% | 47.6% |
Shares
| Measure | Novartis | Industry median |
|---|---|---|
| Shares Outstanding | 1,908,150,000 | 58,127,000 |
| Shares Change (YoY) | -3.93% | 10.9% |
| Float | 1,908,150,000 | 49,136,700 |
| Shares Held by Insiders | 0.00% | 11.6% |
| Shares Held by Institutions | 7.11% | 59.4% |
Taxes
| Measure | Novartis | Industry median |
|---|---|---|
| Income Tax | $2.39B | $79.87K |
| Effective Tax Rate | 14.6% | 20.6% |
Scores
| Measure | Novartis | Industry median |
|---|---|---|
| Graham Number | $59.18 | $18.73 |
| Graham Upside | -60.6% | -45.1% |
| Altman Z-Score | 2.58 | -0.22 |
| Piotroski F-Score | 7 | 4 |
Calculated by StockData from Novartis's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.